Compare Stocks → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CYADNASDAQ:EVLONASDAQ:KTOVNASDAQ:NERVNASDAQ:PHAS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYADCelyad Oncology$0.60$0.67$0.46▼$3.07$15.91MN/AN/A3,009 shsEVLOEvelo Biosciences$0.05+3.4%$0.05$0.03▼$13.93$868K2.0340,811 shs485 shsKTOVPurple Biotech$0.51+4.1%$4.16$2.20▼$14.40$8.06M2.371.18 million shs270,939 shsNERVMinerva Neurosciences$2.45-2.8%$3.48$2.29▼$13.49$17.13M0.21101,123 shs5,770 shsPHASPhaseBio Pharmaceuticals$0.00$0.07▼$4.08$3.50M2.57848,888 shsN/A10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYADCelyad Oncology0.00%0.00%0.00%0.00%-15.71%EVLOEvelo Biosciences+4.00%+0.57%-11.60%-35.85%-98.52%KTOVPurple Biotech+4.63%+18.05%-23.60%-15.95%-74.11%NERVMinerva Neurosciences-0.40%+2.02%-5.26%-67.32%+8.15%PHASPhaseBio Pharmaceuticals0.00%0.00%0.00%0.00%-76.19%Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYADCelyad OncologyN/AN/AN/AN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AKTOVPurple BiotechN/AN/AN/AN/AN/AN/AN/AN/ANERVMinerva Neurosciences3.6204 of 5 stars3.05.00.04.61.80.00.0PHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYADCelyad OncologyN/AN/AN/AN/AEVLOEvelo Biosciences2.00HoldN/AN/AKTOVPurple BiotechN/AN/AN/AN/ANERVMinerva Neurosciences2.00Hold$11.00348.98% UpsidePHASPhaseBio PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsLatest NERV, CYAD, PHAS, KTOV, and EVLO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/27/2024NERVMinerva NeurosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$11.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYADCelyad Oncology$110K144.65N/AN/A$0.20 per share3.00EVLOEvelo BiosciencesN/AN/AN/AN/A($0.92) per shareN/AKTOVPurple Biotech$1M8.06N/AN/A$5.56 per share0.09NERVMinerva NeurosciencesN/AN/AN/AN/A($4.07) per shareN/APHASPhaseBio Pharmaceuticals$818K0.00N/AN/A($1.93) per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYADCelyad Oncology-$9.14MN/A0.00∞N/AN/AN/AN/AN/AEVLOEvelo Biosciences-$114.53M-$13.29N/A∞N/AN/AN/A-189.58%5/13/2024 (Estimated)KTOVPurple Biotech-$5.85M-$3.00N/AN/AN/AN/AN/AN/AN/ANERVMinerva Neurosciences-$30M-$4.65N/AN/AN/AN/AN/A-50.27%5/20/2024 (Estimated)PHASPhaseBio Pharmaceuticals-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/ALatest NERV, CYAD, PHAS, KTOV, and EVLO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/22/2024Q4 2023NERVMinerva Neurosciences-$0.88-$1.19-$0.31-$1.19N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYADCelyad OncologyN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/AKTOVPurple BiotechN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYADCelyad OncologyN/AN/AN/AEVLOEvelo BiosciencesN/A0.480.48KTOVPurple BiotechN/A2.22N/ANERVMinerva NeurosciencesN/A12.5712.58PHASPhaseBio PharmaceuticalsN/A0.470.47OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYADCelyad OncologyN/AEVLOEvelo Biosciences0.31%KTOVPurple Biotech30.72%NERVMinerva Neurosciences34.56%PHASPhaseBio Pharmaceuticals49.02%Insider OwnershipCompanyInsider OwnershipCYADCelyad Oncology0.94%EVLOEvelo Biosciences1.02%KTOVPurple Biotech2.98%NERVMinerva Neurosciences6.40%PHASPhaseBio Pharmaceuticals9.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCYADCelyad Oncology9526.52 million26.28 millionNot OptionableEVLOEvelo Biosciences6618.98 million18.79 millionNo DataKTOVPurple Biotech915.73 millionN/ANot OptionableNERVMinerva Neurosciences96.99 million6.55 millionNot OptionablePHASPhaseBio Pharmaceuticals6049.86 million44.92 millionNot OptionableNERV, CYAD, PHAS, KTOV, and EVLO HeadlinesSourceHeadlineModified Release Neurology Therapeutics Report 202…pharmiweb.com - February 19 at 2:09 PMVelia Therapeutics Appoints Michael York as Chief Business Officerfinance.yahoo.com - December 14 at 8:55 AMLeading innovators in GLP-1 analogues for the pharmaceutical industrypharmaceutical-technology.com - November 6 at 7:00 AMAlcami Announces CEO Transitionfinance.yahoo.com - June 5 at 10:33 AM8-K: PhaseBio Pharmaceuticals Incmarketwatch.com - May 12 at 2:46 AMAbsci Corporation: Absci Reports Fourth Quarter and Full Year 2022 Financial and Operating Resultsfinanznachrichten.de - March 31 at 6:59 PMBioCryst Pharmaceuticals, Inc.: BioCryst Appoints Dr. Nancy Hutson as Chair of the Boardfinanznachrichten.de - March 31 at 1:59 PMBioCryst Appoints Dr. Nancy Hutson as Chair of the Boardfinance.yahoo.com - March 31 at 8:59 AMCardiomyopathy Medication Market Size and Forecast till 2031marketwatch.com - March 22 at 1:16 PMCardiomyopathy Medication Market Emerging Demand and Drive Growth by 2028 with Top Countries Datamarketwatch.com - February 28 at 1:24 PMJi Xing obtains global rights to cardiovascular candidate from Phasebiobioworld.com - February 9 at 7:59 AMBankrupt PhaseBio settles with investor-partner, handing off late-stage drugendpts.com - January 18 at 11:29 PMSFJ Pharmaceuticals Announces Closing of Transfer of Bentracimab Assets from PhaseBio Pharmaceuticalsbenzinga.com - January 17 at 12:24 PMBankruptcy court approves PhaseBio's $32.9M asset transfer dealbizjournals.com - January 5 at 7:47 PMBankrupt PhaseBio Identifies Chiesi as Lead Bidder for Bentracimab Assetsmarketwatch.com - November 8 at 12:22 AMShort Volatility Alert: PhaseBio Pharmaceuticals, Inc.benzinga.com - November 4 at 2:57 PMWhy Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day Sessionmsn.com - November 2 at 6:43 PMWhy Goodyear Tire & Rubber Shares Are Trading Lower; Here Are 24 Stocks Moving Premarketmsn.com - November 1 at 12:30 PMPhaseBio Pharmaceuticals 10% Owner Trades Company's Stockbenzinga.com - October 27 at 4:54 PMPhaseBio Files for Bankruptcy Following Blackstone-Backed Partner’s Lawsuitwsj.com - October 25 at 5:37 AMPhaseBio files for bankruptcy, has a potential deal to sell its assets for up to $100Mbizjournals.com - October 25 at 5:37 AMPhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code (Businesswire)avanza.se - October 24 at 12:07 PMAs top investor makes its play to grab lead drug, PhaseBio counters with Chapter 11, stalking-horse bidendpts.com - October 24 at 12:07 PMPhaseBio Pharma Files For Chapter 11 Bankruptcy Protectionnasdaq.com - October 24 at 12:07 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioStock market today: Wall Street falls on double dose of disappointing economic data, as Meta sinksApril 25, 2024 2:14 AMView Stock market today: Wall Street falls on double dose of disappointing economic data, as Meta sinksFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains ImminentCan Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? April 9, 2024 6:07 AMView Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? Penny Stock Quantum-Si Incorporated Readies For Lift-OffApril 9, 2024 7:14 AMView Penny Stock Quantum-Si Incorporated Readies For Lift-OffAll Headlines Company DescriptionsCelyad OncologyNASDAQ:CYADCelyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.Evelo BiosciencesNASDAQ:EVLOEvelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Purple BiotechNASDAQ:KTOVPurple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. is headquartered in Tel Aviv, Israel.Minerva NeurosciencesNASDAQ:NERVMinerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.PhaseBio PharmaceuticalsNASDAQ:PHASPhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.